Skip to main content

Miguel Chillon Rodriguez

Dr. M. Chillon has been a senior ICREA researcher since 2001 and Director of the UAB-VHIR Joint Unit since 2017. He obtained his doctorate in Genetics at Hospital Duran i Reynals in 1994. Dr. M. Chillon is Director of the Production Unit of Vectors since 2004, Associate Professor at the UAB since 2005, Principal Investigator of the VHIR since 2017, Co-Chair of the Platform for Advanced Therapies of the European organization EATRIS since 2016, coordinator of the eCORE AVANT of the VHIR since 2022, and scientific advisor of different patient organizations and biotechnological spin-offs

Institutions of which they are part

Head of group
Gene Therapy at Nervous System
Vall Hebron Institut de Recerca

Miguel Chillon Rodriguez

Institutions of which they are part

Head of group
Gene Therapy at Nervous System
Vall Hebron Institut de Recerca

Dr. M. Chillon has been a senior ICREA researcher since 2001 and Director of the UAB-VHIR Joint Unit since 2017. He obtained his doctorate in Genetics at Hospital Duran i Reynals in 1994. Dr. M. Chillon is Director of the Production Unit of Vectors since 2004, Associate Professor at the UAB since 2005, Principal Investigator of the VHIR since 2017, Co-Chair of the Platform for Advanced Therapies of the European organization EATRIS since 2016, coordinator of the eCORE AVANT of the VHIR since 2022, and scientific advisor of different patient organizations and biotechnological spin-offs

Dr. M. Chillon created his research group in 2001 focused from the beginning on four main objectives: (1) gene therapy for cognitive deficits associated with aging; (2) gene therapy for autoimmune diseases; (3) gene therapy for rare diseases that affect the nervous system and (4) development of more efficient gene therapy vectors. Dr. Chillon is the author of 76 scientific articles, 3 reviews, 5 book chapters, editor of 1 book (H index: 27; 3470 citations, Scopus), and has directed 14 doctoral theses (4 in progress) and 22 students of Master. In the last five years, Dr. Chillon has obtained different national and international projects such as the European Joint Program-Rare Diseases AC20/00051; Society Challenges. PID2019-104034RB-I00; Challenges Collaboration RTC2019-006879-1; RICORS of the ISCIII RD21/0017/0008; Santander Foundation (2020); CERVERA IDI-2020-0258; ALS International (2018-0512); SmartMoney-UAB (2017); and Marathon TV3, 201607.10. Regarding technology transfer, Dr. Chillon's group has generated 10 patents and founded 2 spin-off companies: NanoTherapix (2009) for gene and cell therapy for diseases of the immune system; and Klogene (2016) for gene therapy of cognitive impairments. He has also founded the Vector Production Unit (UPV) to value the knowledge generated. Currently, the UPV is the first supplier of Ad and AAV vectors to Spanish groups and has the TECNIO Quality accreditation and ISO9001:2015 accreditation. Finally, in recognition of his career, Dr. M Chillón received the "Transfer Award" in 2018 from the Social Council of the UAB.

Projects

Red Española de Adenovirus: desde la biología básica a la nanobiomedicina

IP: Miguel Chillon Rodriguez
Collaborators: -
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 0.01
Reference: RED2022-134221-T
Duration: 01/06/2023 - 31/05/2025

Ministerio de Ciencia

Use of chimeric chronokines for neurodegenerative diseases and cognitive impairments associated with aging

IP: Miguel Chillon Rodriguez
Collaborators: Laia Perez Lasarte, David Ramirez Gomez
Funding agency: Fundació Institut de Recerca HUVH
Funding: 102820.06
Reference: VHIR-PHD-2023-007
Duration: 01/02/2024 - 30/01/2028

ESTUDIO Y DESARROLLO DE LA PRIMERA PLATAFORMA TECNOLÓGICA DE ENSAYOS PARA VIRUS ADENOASOCIADOS EN TERÁPIA GÉNICA

IP: Miguel Chillon Rodriguez
Collaborators: Susana Miravet Delgado, Laia Rubio Ortega, Marina Tarrés Mercader
Funding agency: Instituto de Salud Carlos III
Funding: 296571
Reference: PMPTA22/00048
Duration: 01/01/2023 - 31/12/2024

MECPer-3D - Personalized MECP2 gene therapy using CRISPR/Cas9 technology coupled to AAV-mediated delivery in 3D cell culture and KI mice

IP: Miguel Chillon Rodriguez
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding:
Reference: ISCIII/ERA-NET/EJPRD/2020/CHILLON
Duration: -

Related news

This gene therapy protects mice against cognitive deficits associated with aging, improves motor function, and delays the onset of diseases such as amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease.

Over the course of two days, experts presented the latest advances in vectors, different gene modification techniques and their transfer to clinical practice.

Related professionals

Consuelo Álvarez Lorenzo

Consuelo Álvarez Lorenzo

Read more
Rivas Catoni, Lisandro Tomás

Rivas Catoni, Lisandro Tomás

Research technician
Cardiovascular Diseases
Read more
Rosa María Bartolomé Comas

Rosa María Bartolomé Comas

Microbiology
Read more
Macias Chimborazo, Valeria

Macias Chimborazo, Valeria

Research technician
Psychiatry, Mental Health and Addictions
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.